So, over the past 2 decades, scientists have changed how they think about treatment for major depressive disorder as their understanding of the brain biology behind depression has changed.

Credit: Getty Images. Exxua is expected to be available in early 2024. The Food and Drug Administration (FDA) has approved Exxua ™ (gepirone hydrochloride extended-release tablets) for the ...

[3] Common comorbid Axis I disorders include: eating disorders, substance-related disorders, panic disorder ... when the major depressive episode often remits, 20% to 30% of patients retain ...

for Exxua ™ (gepirone hydrochloride extended-release [ER]) for the treatment of major depressive disorder (MDD). Exxua (formerly known as Travivo) is a novel oral serotonin (5HT) 1A receptor ...

If you have been diagnosed with major depressive disorder, you’ll want to get treatment as soon as possible. To get the care you need, it’s important you find a specialist that fits your needs.

Data suggests that more than 8.3% of U.S. adults experienced a major depressive episode in 2021. Some people with MDD never get treatment. However, most people with the disorder can learn to cope ...

But recent findings estimate that these drugs don’t work for as many as 55 percent of people with major depressive disorder (MDD ... antidepressant treatment. Research shows NMDA receptor ...

and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for major depressive disorder, or MDD, later this year. Watertown, Mass.-based Neumora NMRA ...

a 10-question diagnostic questionnaire used by mental-health professionals to measure the severity of depressive symptoms. The treatment also failed to meet a secondary endpoint of change from ...

Mona Chitre, PharmD, CGP: There are health care disparities in major depressive disorder. We absolutely see them come through in our data as well as in national publications. One in every 2 ...